Physicians' Academy for Cardiovascular Education

Recent clinical insights into icosapent ethyl

10' education - Oct. 3, 2022 - Prof. Deepak Bhatt, MD - Boston, MA, USA

Video navigation menu

  • The design and findings of REDUCE-IT 0:29
  • Total events analysis 4:15
  • Side effects 5:11
  • Subsequent analyses 6:56
  • REDUCE-IT EPA 9:33
  • REDUCE-IT REVASC 11:18
  • REDUCE-IT PCI and REDUCE-IT CABG 12:06
  • REDUCE-IT Prior MI 12:52

Transcript

Show transcript

Educational information

This lecture by Prof. Bhatt was part of the EBAC-accredited symposium "New frontiers in ASCVD risk reduction: integrating icosapent ethyl in clinical practice" held during the ESC congress 2022.

Faculty

Deepak Bhatt, MD, is executive director of Interventional Cardiovascular Programs at Brigham and Women’s Hospital and professor of medicine at Harvard Medical School, Boston, MA, USA.

Disclosures

This recording was independently developed under auspices of PACE-cme. The views expressed in this recording are those of the individual presenter and do not necessarily reflect the views of PACE-cme.

Funding

Funding for this educational program was provided by an unrestricted educational grant from Amarin.

View the slides of this presentation

The information and data provided in this program were updated and correct at the time of the program development, but may be subject to change.

Share this page with your colleagues and friends: